AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23860050
Drug: Early feeding
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early feeding (mean time of first oral feeding 2.5 + 0.7 days)
Trial: 23860050
Drug: Late feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late feeding (mean time of first oral feeding 5.3 + 0.6 days)
Trial: 21869636
Drug: Wobble board
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wobble board balance training for 9 weeks, twice a week
Trial: 8857654
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g fluoride dentifrice
Trial: 8857654
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g fluoride dentifrice
Trial: 26775268
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (basic antiplatelet and lipid-lowering therapy only)
Trial: 22516525
Drug: Nonpharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatment (diet and fluid restriction)
Trial: 22516525
Drug: Nonpharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatment (daily weighing)
Trial: 22516525
Drug: Nonpharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpharmacologic treatment (exercise)
Trial: 18628451
Drug: Ixabepilone as
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone as monotherapy
Trial: 11836283
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE, 200 mg im weekly)
Trial: 11836283
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate plus depot medroxyprogesterone acetate (DMPA, 300 mg im once)
Trial: 10433577
Drug: Chromatographically purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromatographically purified rabies vaccine (CPRV) 0.5 mL
Trial: 10433577
Drug: Human diploid
RxNorm normalized name: rabies vaccine, human diploid cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human diploid cell rabies vaccine (HDCV) 1.0 mL
Trial: 2206065
Drug: Intravenous mezlocillin
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mezlocillin for 48 hours followed by oral ampicillin until delivery
Trial: 12122510
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and oral placebo
Trial: 30413383
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (stage IV)
Trial: 27117874
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 12 mg oral dexamethasone with 4 days of placebo
Trial: 27117874
Drug: 5-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of oral prednisone 60 mg a day
Trial: 20714145
Drug: Biapenem 300
RxNorm normalized name: biapenem
DrugBank: Biapenem (DB13028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biapenem 300 mg
Trial: 20714145
Drug: Imipenem/cilastatin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin 500 mg/500 mg
Trial: 17094981
Drug: Intravenous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous low-dose ACTH
Trial: 16152759
Drug: PEG‐IFN alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alpha 2a (180 microg per week) and RBV (1000‐1200 mg daily)
Trial: 10363624
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg without antacid
Trial: 10363624
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg with antacid (concomitantly)
Trial: 10363624
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg one hour after antacid administration
Trial: 7549753
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with four nutrients (vitamin A, riboflavin, zinc, and selenium), one capsule twice a week for 1 year
Trial: 7549753
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one capsule twice a week for 1 year
Trial: 31943717
Drug: TAVR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAVR with periprocedural anticoagulation with unfractionated heparin
Trial: 26066736
Drug: Doxorubicin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (75 mg/m²) and ifosfamide (2.5 g/m²/d) on days 1-3 with mesna 500 mg/m²/dose
Trial: 26066736
Drug: Gemcitabine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (900 mg/m² on days 1, 8) and docetaxel (100 mg/m² on day 8)
Trial: 15622454
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPG 7909 (0.125, 0.5, or 1.0 mg)
Trial: 11260410
Drug: Fluvastatin (FLU)
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin (FLU) 40 mg/day
Trial: 8045978
Drug: alpha MSH
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha MSH (2.5 mg as an iv bolus 60 min after the start of saline infusion)
Trial: 8045978
Drug: CRH plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRH plus alpha MSH (injected 60 min after the start of CRH infusion)
Trial: 28286971
Drug: YOMI program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YOMI program (five-week intervention, twice a week)
Trial: 23615640
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of estradiol (E2) daily for 12 weeks
Trial: 23615640
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of estradiol (E2) and 0.5 mg of norethindrone acetate (NA) daily for 12 weeks
Trial: 15276594
Drug: Interferon administered
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon administered three times weekly with weight-based ribavirin
Trial: 15276594
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon with weight-based ribavirin
Trial: 15276594
Drug: Interferon and
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon and ribavirin therapy
Trial: 9466164
Drug: RS-8359, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359, oral dosing up to 300 mg
Trial: 7877116
Drug: High-risk nonusers
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk nonusers (thinking about using steroids)
Trial: 7877116
Drug: Low-risk nonusers
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-risk nonusers (not thinking about using steroids)
Trial: 7877116
Drug: Steroid users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid users
Trial: 3282481
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride (maximum dosage of 300 mg/d, mean dosage at week 8 of 82.8 mg/d)
Trial: 18240203
Drug: Sequential disease‐modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential disease‐modifying antirheumatic drug monotherapy (group 1)
Trial: 17405834
Drug: Step‐up combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step‐up combination therapy (group 2)
Trial: 17405834
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with tapered high‐dose prednisone (group 3)
Trial: 17014731
Drug: Supervised Nordic
RxNorm normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised Nordic Walking twice a week for eight weeks under supervision of a specially trained instructor
Trial: 10069525
Drug: Secretin infusion
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin infusion (0.1 CU/kg.h) for 60 min
Trial: 10069525
Drug: Secretin +
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin + CCK infusion (0.5 IDU/kg.h) for 60 min
Trial: 11104404
Drug: Secretin infusion
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin infusion
Trial: 10069525
Drug: Secretin +
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secretin + CCK infusion
Trial: 31359519
Drug: Crocin 15
RxNorm normalized name: CROCIN
DrugBank: Crocin (DB11874)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin 15 mg/day
Trial: 28805758
Drug: noophen (γ‐amino‐β‐phenylbutyric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride) 15‐20 mg/kg per day (2‐3 times perorally) for 2 months
Trial: 26272250
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil (FA) administered i.v. 15 min before skin incision in group F.
Trial: 26272250
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered i.v. 15 min before skin incision in group C.
Trial: 11786587
Drug: Oral megestrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral megestrol acetate 800 mg/d liquid suspension plus placebo
Trial: 11786587
Drug: Oral dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dronabinol 2.5 mg twice a day plus placebo
Trial: 11786587
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (dronabinol and megestrol acetate)
Trial: 11786587
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Anorexia/Cachexia Therapy questionnaire
Trial: 7926080
Drug: Danazol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (400 mg orally twice daily for 4 months)
Trial: 27041263
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil (prophylactic administration)
Trial: 21374895
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with high disability and limitations in daily living
Trial: 2483979
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment
Trial: 31447131
Drug: Niacin/Laropiprant (2000/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin/Laropiprant (2000/40 mg/d)
Trial: 28891419
Drug: Listening to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listening to Holy Qur'an recitation in combination with endurance‐resistance training (n = 28)
Trial: 26568566
Drug: Intermittent ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent ART (I-ART) for 2 years, consisting of 6 month periods on once-daily boosted-PI-based ART, alternating with 6 month periods without ART.
Trial: 11486703
Drug: Granulocyte colony
RxNorm normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Granulocyte colony stimulating factor (G‐CSF)
Trial: 19237716
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d)
Trial: 11560871
Drug: Diltiazem (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (200 mg)
Trial: 9934573
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of lidocaine hydrochloride
Trial: 9934573
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of saline
Trial: 7946688
Drug: iohexol 350
RxNorm normalized name: iohexol 350 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 350 mg I/ml with NaCl 28 mmol/l
Trial: 27031165
Drug: Effective microorganism-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective microorganism-X (EM-X) supplementation (70 ml·day(‐1))
Trial: 20078917
Drug: Ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 800 mg, 3 times daily as needed for up to 7 days
Trial: 20078917
Drug: Cyclobenzaprine 5
RxNorm normalized name: cyclobenzaprine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 5 mg, 3 times daily as needed for up to 7 days
Trial: 20078917
Drug: Both ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both ibuprofen and cyclobenzaprine, 3 times daily as needed for up to 7 days
Trial: 18616688
Drug: Trazodone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50 to 150 mg at bedtime) for 12 weeks
Trial: 16911750
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment (10 treatments, on business days)
Trial: 16911750
Drug: Spaced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced treatment (five treatments, on spaced business days)
Trial: 2126741
Drug: Hydrophilic NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrophilic NTG oral spray (0.8 mg)
Trial: 2126741
Drug: Lipophilic NTG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipophilic NTG oral spray (0.8 mg)
Trial: 22470104
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine lozenge (NL)
Trial: 28060837
Drug: CSL‐111 (reconstituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL‐111 (reconstituted HDL) 40 mg/kg, administered as 4 weekly intravenous infusions
Trial: 19586828
Drug: 1 mg/mL
RxNorm normalized name: urea 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL morphine and 10 microg/mL nalbuphine (1:100)
Trial: 19586828
Drug: 1 mg/mL
RxNorm normalized name: urea 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/mL morphine
Trial: 11210399
Drug: Carbatrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbatrol (200 mg) with a high-fat meal
Trial: 11210399
Drug: Carbatrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbatrol (200 mg) fasted
Trial: 11210399
Drug: Carbatrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbatrol (200 mg) sprinkled over applesauce (but otherwise fasted)
Trial: 7542052
Drug: Fluvoxamine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (200 mg/day for 4 weeks or individualized dosing for 6 weeks)
Trial: 356970
Drug: Chemoimmunotherapy (DTIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5; methanol extracted residue of bacillus Calmette-Guérin 0.5 mg intradermally every 5 weeks)
Trial: 356970
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (DTIC 250 mg/m2 iv, Days 1-5; actinomycin D 0.5 mg/day iv, Days 1-5)
Trial: 20445533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of benazepril and valsartan
Trial: 20445533
Drug: Control (single-agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (single-agent treatment with benazepril or valsartan)
Trial: 18349171
Drug: Beta-blockers (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (specific mention of metoprolol and other beta-blockers)
Trial: 8706442
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol in combination with laminaria or tamoxifen
Trial: 3865687
Drug: PGE2 (100-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2 (100-500 micrograms ml-1)
Trial: 3865687
Drug: PGF2 alpha
RxNorm normalized name: Prostaglandin PGF2 alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGF2 alpha (0.1-100 micrograms ml-1)
Trial: 3865687
Drug: Acetylcholine (0.1-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine (0.1-50 mg ml-1)
Trial: 31492716
Drug: IV glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV glucose infusion (10% glucose at 410 mL/h)
Trial: 31492716
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose supplementation (2% concentration soft drink)
Trial: 26768929
Drug: 3mg/kg 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg 0.5% prilocaine + 2 mL (100mg) tramadol
Trial: 26768929
Drug: 3mg/kg 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg 0.5% prilocaine + 2 mL (8 mg) lornoxicam
Trial: 24657033
Drug: N-acetylcystein 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcystein 150 mg/kg followed by 50 mg/kg for 6 hours in 0.9% saline
Trial: 18064525
Drug: 2 l/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 l/min oxygen via nasal prongs
Trial: 18064525
Drug: 6 l/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 l/min oxygen through a rebreathing face mask
Trial: 11835022
Drug: Oral GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GP IIb/IIIa inhibitors
Trial: 14519089
Drug: Intravenous GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GP IIb/IIIa receptor blockers
Trial: 6743481
Drug: Cimetidine 600
RxNorm normalized name: cimetidine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 600 mg twice daily
Trial: 24717711
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fluoride therapy)
Trial: 17454195
Drug: Chemotherapy (CHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHT) without GnRH‐a
Trial: 2057991
Drug: Computer program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer program predicting warfarin dosage adjustments
Trial: 29304199
Drug: monovalent high‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monovalent high‐dose type 2‐specific IPV (mIPV2HD)
Trial: 19058332
Drug: Antioxidant enteral
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant enteral supplement
Trial: 16837793
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy at the dose of 0.23 mg/kg/week s.c.
Trial: 12802751
Drug: Oral pleconaril
RxNorm normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pleconaril
Trial: 9554153
Drug: Breast-feeding (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast-feeding (at least once daily)
Trial: 1527286
Drug: Anistreplase (APSAC)
RxNorm normalized name: Anistreplase
DrugBank: Anistreplase (DB00029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anistreplase (APSAC) 30 U/2 to 5 min with aspirin (160 mg/day) and intravenous heparin
Trial: 1527286
Drug: Alteplase (rt-PA)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase (rt-PA) 100 mg/3 h with aspirin (160 mg/day) and intravenous heparin
Trial: 31948255
Drug: Physiotherapy intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy intervention (daily exercises aimed at the foot arch)
Trial: 18796517
Drug: Genistein aglycone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein aglycone (54 mg daily)
Trial: 18214021
Drug: High-iron rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-iron rice (3.21 mg/kg Fe)
Trial: 18214021
Drug: Control rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control rice (0.57 mg/kg Fe)